Home › NDC Lookup › RxCUI directory › RxCUI 686420

Erythromycin ethylsuccinate 80 MG/ML Oral Suspension [EryPed] — RxCUI 686420

RxNorm drug concept · Semantic branded drug
RxCUI 686420 Semantic branded drug · SBD ● Current RxNorm concept 3 FDA products 3 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI686420
Official nameErythromycin ethylsuccinate 80 MG/ML Oral Suspension [EryPed]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asEryPed 400 Oral Suspension; EryPed 400 MG in 5 mL Oral Suspension; EES 80 MG/ML Oral Suspension [EryPed]; EryPed 400 MG per 5 ML Oral Suspension; EryPed 80 MG/ML Oral Suspension
FDA products mapped3
Package NDCs mapped3
Reported Medicaid activity (SDUD)66 prescriptions · 1 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Erythromycin Ophthalmic: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It treats minor bacterial infections on the surface of the eye, affecting the conjunctiva and/or cornea. It's also used in newborns to help prevent eye infections from gonorrhea or...
  • For an eye infection, you apply a ribbon of ointment about 1 cm long directly to the infected area. Depending on how severe it is, this can be done up to 6 times a day. Follow your...
  • No. The ointment should stay in the eye and not be flushed out after you apply it. Your vision may feel a bit different for a moment, but that's not a reason to rinse it away.
  • Should I rinse it out after putting it in?
📖 Read our full Erythromycin Ophthalmic guide →

🕸️ Concept Web — How Erythromycin ethylsuccinate 80 MG/ML Oral Suspen... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Erythromycin ethylsuccinate 80 MG/ML Oral Suspension [EryPed] RxCUI 686420

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 2

    The active substance itself — no strength, form, or brand attached yet.

    • Erythromycin 4053
    • Erythromycin ethylsuccinate 4056
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • EryPed 203253
  3. Dose forms 13

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Erythromycin Oral Suspension 372062
    • Erythromycin ethylsuccinate Oral Suspension 2648213
    • Erythromycin Oral Liquid Product 1164503
    • Erythromycin Oral Product 1164504
    • Erythromycin ethylsuccinate Oral Liquid Product 2663576
    • Erythromycin ethylsuccinate Oral Product 2662042
    • Erythromycin Oral Suspension [EryPed] 544533
    • Erythromycin ethylsuccinate Oral Suspension [EryPed] 2656354
    • +5 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 14 of 19 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Erythromycin ethylsuccinate 80 MG/ML Oral Suspension SCD · 686418
  • Erythromycin ethylsuccinate 80 MG/ML SCDC · 686417
  • Erythromycin Oral Suspension SCDF · 372062
  • Erythromycin ethylsuccinate Oral Suspension SCDFP · 2648213
  • Erythromycin Oral Liquid Product SCDG · 1164503
  • Erythromycin Oral Product SCDG · 1164504
  • Erythromycin ethylsuccinate Oral Liquid Product SCDGP · 2663576
  • Erythromycin ethylsuccinate Oral Product SCDGP · 2662042

Brand-Name Concepts

  • Erythromycin ethylsuccinate 80 MG/ML [EryPed] SBDC · 686419
  • Erythromycin Oral Suspension [EryPed] SBDF · 544533
  • Erythromycin ethylsuccinate Oral Suspension [EryPed] SBDFP · 2656354
  • EryPed Oral Liquid Product SBDG · 1168952
  • EryPed Oral Product SBDG · 1168953
  • EryPed BN · 203253

📦 FDA Products & Package NDCs

3 products · 3 package NDCs
3 package NDCs map to RxCUI 686420 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
24338-0130-13 100 mL in 1 BOTTLE (24338-130-13) Ery-Ped Azurity Pharmaceuticals, Inc. (formerly Arbor Pharmaceuticals) 2012-06-14
24338-0132-13 100 mL in 1 BOTTLE (24338-132-13) Ery-Ped Azurity Pharmaceuticals, Inc. (formerly Arbor Pharmaceuticals) 2011-07-05
80005-0155-18 100 mL in 1 BOTTLE (80005-155-18) Ery-Ped Carnegie Pharmaceuticals LLC 2025-01-15
Observed labelers: Azurity Pharmaceuticals, Inc. (formerly Arbor Pharmaceuticals) (2) · Carnegie Pharmaceuticals LLC (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.